Generic oncology drugs: are they all safe?

Y. Tony Yang, Sumimasa Nagai, Brian K. Chen, Zaina P. Qureshi, Akida A. Lebby, Samuel Kessler, Peter Georgantopoulos, Dennis W. Raisch, Oliver Sartor, Terhi Hermanson, Robert C. Kane, William J. Hrushesky, Joshua J. Riente, Le Ann B Norris, Laura R. Bobolts, James Olen Armitage, Charles L. Bennett

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Although the availability of generic oncology drugs allows access to contemporary care and reduces costs, there is international variability in the safety of this class of drugs. In this Series paper, we review clinical, policy, safety, and regulatory considerations for generic oncology drugs focusing on the USA, Canada, the European Union (EU), Japan, China, and India. Safety information about generic formulations is reviewed from one agent in each class, for heavy metal drugs (cisplatin), targeted agents (imatinib), and cytotoxic agents (docetaxel). We also review regulatory reports from Japan and the USA, countries with the largest pharmaceutical expenditures. Empirical studies did not identify safety concerns in the USA, Canada, the EU, and Japan, where regulations and enforcement are strong. Although manufacturing problems for generic pharmaceuticals exist in India, where 40% of all generic pharmaceuticals used in the USA are manufactured, increased inspections and communication by the US Food and Drug Administration are occurring, facilitating oversight and enforcement. No safety outbreaks among generic oncology drugs were reported in developed countries. For developing countries, oversight is less intensive, and concerns around drug safety still exist. Regulatory agencies should collaboratively develop procedures to monitor the production, shipment, storage, and post-marketing safety of generic oncology drugs. Regulatory agencies for each country should also aim towards identical definitions of bioequivalence, the cornerstone of regulatory approval.

Original languageEnglish (US)
Pages (from-to)e493-e501
JournalThe Lancet Oncology
Volume17
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Generic Drugs
Safety
Japan
docetaxel
European Union
Pharmaceutical Preparations
Canada
India
Therapeutic Equivalency
Cytotoxins
United States Food and Drug Administration
Health Expenditures
Heavy Metals
Marketing
Developed Countries
Cisplatin
Developing Countries
Disease Outbreaks
China
Costs and Cost Analysis

ASJC Scopus subject areas

  • Oncology

Cite this

Yang, Y. T., Nagai, S., Chen, B. K., Qureshi, Z. P., Lebby, A. A., Kessler, S., ... Bennett, C. L. (2016). Generic oncology drugs: are they all safe? The Lancet Oncology, 17(11), e493-e501. https://doi.org/10.1016/S1470-2045(16)30384-9

Generic oncology drugs : are they all safe? / Yang, Y. Tony; Nagai, Sumimasa; Chen, Brian K.; Qureshi, Zaina P.; Lebby, Akida A.; Kessler, Samuel; Georgantopoulos, Peter; Raisch, Dennis W.; Sartor, Oliver; Hermanson, Terhi; Kane, Robert C.; Hrushesky, William J.; Riente, Joshua J.; Norris, Le Ann B; Bobolts, Laura R.; Armitage, James Olen; Bennett, Charles L.

In: The Lancet Oncology, Vol. 17, No. 11, 01.11.2016, p. e493-e501.

Research output: Contribution to journalReview article

Yang, YT, Nagai, S, Chen, BK, Qureshi, ZP, Lebby, AA, Kessler, S, Georgantopoulos, P, Raisch, DW, Sartor, O, Hermanson, T, Kane, RC, Hrushesky, WJ, Riente, JJ, Norris, LAB, Bobolts, LR, Armitage, JO & Bennett, CL 2016, 'Generic oncology drugs: are they all safe?', The Lancet Oncology, vol. 17, no. 11, pp. e493-e501. https://doi.org/10.1016/S1470-2045(16)30384-9
Yang YT, Nagai S, Chen BK, Qureshi ZP, Lebby AA, Kessler S et al. Generic oncology drugs: are they all safe? The Lancet Oncology. 2016 Nov 1;17(11):e493-e501. https://doi.org/10.1016/S1470-2045(16)30384-9
Yang, Y. Tony ; Nagai, Sumimasa ; Chen, Brian K. ; Qureshi, Zaina P. ; Lebby, Akida A. ; Kessler, Samuel ; Georgantopoulos, Peter ; Raisch, Dennis W. ; Sartor, Oliver ; Hermanson, Terhi ; Kane, Robert C. ; Hrushesky, William J. ; Riente, Joshua J. ; Norris, Le Ann B ; Bobolts, Laura R. ; Armitage, James Olen ; Bennett, Charles L. / Generic oncology drugs : are they all safe?. In: The Lancet Oncology. 2016 ; Vol. 17, No. 11. pp. e493-e501.
@article{07a880d0f3ed4f38ac1731ed1ef6e2c5,
title = "Generic oncology drugs: are they all safe?",
abstract = "Although the availability of generic oncology drugs allows access to contemporary care and reduces costs, there is international variability in the safety of this class of drugs. In this Series paper, we review clinical, policy, safety, and regulatory considerations for generic oncology drugs focusing on the USA, Canada, the European Union (EU), Japan, China, and India. Safety information about generic formulations is reviewed from one agent in each class, for heavy metal drugs (cisplatin), targeted agents (imatinib), and cytotoxic agents (docetaxel). We also review regulatory reports from Japan and the USA, countries with the largest pharmaceutical expenditures. Empirical studies did not identify safety concerns in the USA, Canada, the EU, and Japan, where regulations and enforcement are strong. Although manufacturing problems for generic pharmaceuticals exist in India, where 40{\%} of all generic pharmaceuticals used in the USA are manufactured, increased inspections and communication by the US Food and Drug Administration are occurring, facilitating oversight and enforcement. No safety outbreaks among generic oncology drugs were reported in developed countries. For developing countries, oversight is less intensive, and concerns around drug safety still exist. Regulatory agencies should collaboratively develop procedures to monitor the production, shipment, storage, and post-marketing safety of generic oncology drugs. Regulatory agencies for each country should also aim towards identical definitions of bioequivalence, the cornerstone of regulatory approval.",
author = "Yang, {Y. Tony} and Sumimasa Nagai and Chen, {Brian K.} and Qureshi, {Zaina P.} and Lebby, {Akida A.} and Samuel Kessler and Peter Georgantopoulos and Raisch, {Dennis W.} and Oliver Sartor and Terhi Hermanson and Kane, {Robert C.} and Hrushesky, {William J.} and Riente, {Joshua J.} and Norris, {Le Ann B} and Bobolts, {Laura R.} and Armitage, {James Olen} and Bennett, {Charles L.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/S1470-2045(16)30384-9",
language = "English (US)",
volume = "17",
pages = "e493--e501",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "11",

}

TY - JOUR

T1 - Generic oncology drugs

T2 - are they all safe?

AU - Yang, Y. Tony

AU - Nagai, Sumimasa

AU - Chen, Brian K.

AU - Qureshi, Zaina P.

AU - Lebby, Akida A.

AU - Kessler, Samuel

AU - Georgantopoulos, Peter

AU - Raisch, Dennis W.

AU - Sartor, Oliver

AU - Hermanson, Terhi

AU - Kane, Robert C.

AU - Hrushesky, William J.

AU - Riente, Joshua J.

AU - Norris, Le Ann B

AU - Bobolts, Laura R.

AU - Armitage, James Olen

AU - Bennett, Charles L.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Although the availability of generic oncology drugs allows access to contemporary care and reduces costs, there is international variability in the safety of this class of drugs. In this Series paper, we review clinical, policy, safety, and regulatory considerations for generic oncology drugs focusing on the USA, Canada, the European Union (EU), Japan, China, and India. Safety information about generic formulations is reviewed from one agent in each class, for heavy metal drugs (cisplatin), targeted agents (imatinib), and cytotoxic agents (docetaxel). We also review regulatory reports from Japan and the USA, countries with the largest pharmaceutical expenditures. Empirical studies did not identify safety concerns in the USA, Canada, the EU, and Japan, where regulations and enforcement are strong. Although manufacturing problems for generic pharmaceuticals exist in India, where 40% of all generic pharmaceuticals used in the USA are manufactured, increased inspections and communication by the US Food and Drug Administration are occurring, facilitating oversight and enforcement. No safety outbreaks among generic oncology drugs were reported in developed countries. For developing countries, oversight is less intensive, and concerns around drug safety still exist. Regulatory agencies should collaboratively develop procedures to monitor the production, shipment, storage, and post-marketing safety of generic oncology drugs. Regulatory agencies for each country should also aim towards identical definitions of bioequivalence, the cornerstone of regulatory approval.

AB - Although the availability of generic oncology drugs allows access to contemporary care and reduces costs, there is international variability in the safety of this class of drugs. In this Series paper, we review clinical, policy, safety, and regulatory considerations for generic oncology drugs focusing on the USA, Canada, the European Union (EU), Japan, China, and India. Safety information about generic formulations is reviewed from one agent in each class, for heavy metal drugs (cisplatin), targeted agents (imatinib), and cytotoxic agents (docetaxel). We also review regulatory reports from Japan and the USA, countries with the largest pharmaceutical expenditures. Empirical studies did not identify safety concerns in the USA, Canada, the EU, and Japan, where regulations and enforcement are strong. Although manufacturing problems for generic pharmaceuticals exist in India, where 40% of all generic pharmaceuticals used in the USA are manufactured, increased inspections and communication by the US Food and Drug Administration are occurring, facilitating oversight and enforcement. No safety outbreaks among generic oncology drugs were reported in developed countries. For developing countries, oversight is less intensive, and concerns around drug safety still exist. Regulatory agencies should collaboratively develop procedures to monitor the production, shipment, storage, and post-marketing safety of generic oncology drugs. Regulatory agencies for each country should also aim towards identical definitions of bioequivalence, the cornerstone of regulatory approval.

UR - http://www.scopus.com/inward/record.url?scp=84995677646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995677646&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(16)30384-9

DO - 10.1016/S1470-2045(16)30384-9

M3 - Review article

C2 - 27819247

AN - SCOPUS:84995677646

VL - 17

SP - e493-e501

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 11

ER -